Treatment of Renal Cell Carcinoma in Collecting Duct Carcinoma or SMARCB1-Deficient RCC
Collecting duct carcinoma and SMARCB1-deficient renal cell carcinoma are rare, histologically distinct subtypes of RCC. They carry specific first-line treatment recommendations that differ from the approach used in clear-cell disease.
Clinical Scenario
This protocol is indicated for patients with confirmed collecting duct carcinoma or SMARCB1-deficient renal cell carcinoma — subtypes that require a dedicated therapeutic strategy.
Treatment Approach — Partial Overview
First-line management is built around cisplatin-based chemotherapy as the recommended strategy. The full protocol also defines additional treatment alternatives for eligible patients.
Complete regimen details, sequencing, and eligibility criteria are available in the full protocol below.
References
- Cisplatin-based ChT is recommended for collecting duct carcinomas and SMARCB1-deficient RCC.
DOI: 10.1016/j.annonc.2024.05.537
View source ↗